Epoetin alfa

From WikiMD's Wellness Encyclopedia

(Redirected from Epomax)

What is Epoetin alfa?[edit | edit source]



What are the uses of this medicine?[edit | edit source]

Epoetin alfa (Retacrit;Epoge; Procrit) used to treat anemia if it is caused by:

  • Epoetin alfa may also be used to reduce the chance you will need RBC transfusions if you are scheduled for certain surgeries where a lot of blood loss is expected.
  • If your hemoglobin level stays too high or if your hemoglobin goes up too quickly, this may lead to serious health problems which may result in death. These serious health problems may happen if you take Epoetin alfa, even if you do not have an increase in your hemoglobin level.

Limitations of Use:

  • Epoetin alfa has not been proven to improve quality of life, fatigue, or well-being.

Epoetin alfa should not be used for treatment of anemia:

  • If you have cancer and you will not be receiving chemotherapy that may cause anemia.
  • If you have a cancer that has a high chance of being cured. Talk with your healthcare provider about the kind of cancer you have.
  • If your anemia caused by chemotherapy treatment can be managed by RBC transfusion.
  • In place of emergency treatment for anemia (RBC transfusions).

Epoetin alfa should not be used to reduce the chance you will need RBC transfusions if:

  • You are scheduled for surgery on your heart or blood vessels.
  • You are able and willing to donate blood prior to surgery.


How does this medicine work?[edit | edit source]

  • Epoetin alfa is a form of erythropoietin (a substance naturally made by the kidneys) that is made in the laboratory.
  • It helps the bone marrow make more red blood cells.
  • Epoetin alfa is a type of antianemic and a type of erythropoiesis-stimulating agent.


Who Should Not Use this medicine ?[edit | edit source]

This medicine cannot be used in patients who:

  • Have cancer and have not been counseled by your healthcare provider about treatment with Epogen.
  • Have high blood pressure that is not controlled (uncontrolled hypertension).
  • Have been told by your healthcare provider that you have or have ever had a type of anemia called Pure Red Cell Aplasia (PRCA) that starts after treatment with Epogen or other erythropoietin protein medicines.
  • Have had a serious allergic reaction to Epogen.

Do not give Epoetin alfa from multiple-dose vials to:

  • Pregnant or breastfeeding women
  • Babies


What drug interactions can this medicine cause?[edit | edit source]

  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.


Is this medicine FDA approved?[edit | edit source]

  • Initial U.S. Approval: 1989


How should this medicine be used?[edit | edit source]

  • Evaluate iron status before and during treatment and maintain iron repletion. Correct or exclude other causes of anemia before initiating treatment.

Recommended dosage:

  • Patients with CKD:
  • Initial dose: 50 to 100 Units/kg 3 times weekly (adults) and 50 Units/kg 3 times weekly (pediatric patients).
  • Individualize maintenance dose. Intravenous route recommended for patients on hemodialysis.
  • Patients on Zidovudine due to HIV-infection: 100 Units/kg 3 times weekly.

Patients with Cancer on Chemotherapy:

  • 40,000 Units weekly or 150 Units/kg 3 times weekly (adults); 600 Units/kg intravenously weekly (pediatric patients ≥ 5 years).

Surgery Patients:

  • 300 Units/kg per day daily for 15 days or 600 Units/kg weekly.

In pregnant women, lactating women, neonates, infants:

  • Use only single-dose vials.

Administration:

  • Epoetin alfa injection products come as a solution (liquid) to inject subcutaneously (just under the skin) or intravenously (into a vein).
  • If you or your caregiver has been trained to give Epoetin alfa shots (injections) at home:
  • Be sure that you read, understand, and follow the "Instructions for Use" that come with Epoetin alfa.
  • Take Epoetin alfa exactly as your healthcare provider tells you to. Do not change the dose ofEpoetin alfa unless told to do so by your healthcare provider.
  • Your healthcare provider will show you how much Epoetin alfa to use, how to inject it, how often it should be injected, and how to safely throw away the used vials, syringes, and needles.
  • If you miss a dose of Epoetin alfa, call your healthcare provider right away and ask what to do.
  • If you take more than the prescribed dose of Epoetin alfa, call your healthcare provider right away.
  • During treatment with Epoetin alfa, continue to follow your healthcare provider's instructions for diet and medicines.
  • Have your blood pressure checked as instructed by your healthcare provider.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form: As Injection:

  • 2,000 Units/mL, 3,000 Units/mL, 4,000 Units/mL, and 10,000 Units/mL in single-dose vials.
  • 20,000 Units/2 mL (10,000 Units/mL) and 20,000 Units/mL in multiple-dose vials containing benzyl alcohol.

This medicine is available in fallowing brand namesː

  • Retacrit; Epogen; Procrit


What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:

Epoetin alfa may cause serious side effects, including:

  • Serious heart problems, such as heart attack or heart failure, and stroke
  • Blood clots
  • High blood pressure
  • Seizures
  • Antibodies to Epoetin alfa
  • Serious allergic reactions
  • Severe skin reactions
  • Dangers of using multiple-dose vials in newborns, infants, and pregnant or breastfeeding women


What special precautions should I follow?[edit | edit source]

  • Evaluate iron status before and during treatment and maintain iron repletion. Correct or exclude other causes of anemia before initiating treatment.
  • Use only single-dose vials for pregnant women, lactating women, neonates, infants.
  • Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit. Use caution in patients with coexistent cardiovascular disease and stroke.
  • Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer.
  • Epoetin alfa is contraindicated in patients with uncontrolled hypertension. Control hypertension prior to initiating and during treatment with Epoetin alfa.
  • Epoetin alfa products increase the risk for seizures in patients with CKD. Increase monitoring of these patients for changes in seizure frequency or premonitory symptoms.
  • Cases of Pure Red Cell Aplasia (PRCA) and of severe anemia, with or without other cytopenias that arise following the development of neutralizing antibodies to erythropoietin have been reported in patients treated with epoetin alfa. If severe anemia and low reticulocyte count develop during Epoetin alfa treatment, withhold Epoetin alfa and evaluate for PRCA.
  • Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria may occur with epoetin alfa products. Discontinue epoetin alfa and manage reactions.
  • Blistering and skin exfoliation reactions including Erythema multiforme and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN), have been reported in patients treated with ESAs (including epoetin alfa). Discontinue Retacrit .
  • Phenylalanine can be harmful to patients with phenylketonuria (PKU). Retacrit contains phenylalanine, a component of aspartame. Contains phenylalanine
  • Epogen from multiple-dose vials contains benzyl alcohol and is contraindicated for use in neonates, infants, pregnant women, and lactating women.


What to do in case of emergency/overdose?[edit | edit source]

Symptoms of overdosage may include:

Management of overdosage:

  • Overdosage should be managed with discontinuation or reduction of epoetin alfa dosage and/or with phlebotomy, as clinically indicated.


Can this medicine be used in pregnancy?[edit | edit source]

  • Retacrit; Epogen from multiple-dose vials contains benzyl alcohol and is contraindicated in pregnant women.
  • The limited available data on epoetin alfa use in pregnant women are insufficient to determine a drug-associated risk of adverse developmental outcomes.


Can this medicine be used in children?[edit | edit source]

  • The multiple-dose vials are formulated with benzyl alcohol and are contraindicated for use in neonates and infants.
  • It is not known if epoetin alfa is safe and effective in treating anemia in children less than 1 month old who have chronic kidney disease and in children less than 5 years old who have anemia caused by chemotherapy.


What are the active and inactive ingredients in this medicine?[edit | edit source]

Retacrit: Active Ingredient: epoetin alfa-epbx Inactive Ingredients:

  • Multiple-dose vials contain benzyl alcohol.
  • All single-dose vials contain calcium chloride dehydrate, glycine, isoleucine, leucine, L-glutamic acid, phenylalanine, polysorbate 20, sodium chloride, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate, and threonine, in water for injection. Sodium hydroxide and hydrochloric acid may be added to adjust the pH.
  • All multiple-dose vials contain benzyl alcohol, L-methionine, polysorbate 20, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate, and sucrose, in water for injection. Sodium hydroxide and hydrochloric acid may be added to adjust the pH.

Epogen: Active ingredient:

  • epoetin alfa

Inactive ingredients:

  • Multiple-dose vials contain benzyl alcohol.
  • All vials contain albumin (human), citric acid, sodium chloride, sodium citrate, and Water for Injection.


Who manufactures and distributes this medicine?[edit | edit source]

Retacrit:

  • Manufactured by Hospira, Inc., a Pfizer Company, Lake Forest, IL USA
  • Distributed by Vifor (International) Inc., Rechenstrasse 37, 9014 St. Gallen, Switzerland

Epogen:

  • Manufactured by: Amgen Inc. One Amgen Center Drive Thousand Oaks, CA U.S.A.


What should I know about storage and disposal of this medication?[edit | edit source]

  • Do not shake Epogen; Retacrit.
  • Store Epogen; Retacrit vials in the carton it comes in to protect from light.
  • Store Epogen; Retacrit in the refrigerator between 36°F to 46°F (2°C to 8°C).
  • Do not freeze Epogen; Retacrit. Do not use Epogen that has been frozen.
  • Throw away multiple-dose vials of Epogen; Retacrit no later than 21 days from the first day that you put a needle into the vial.
  • Single-dose vials of Epogen; Retacrit should be used only one time. Throw the vial away after use even if there is medicine left in the vial.


Epoetin alfa Resources
Wikipedia

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Deepika vegiraju